Albert Reising

Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial

A. Ari Hakimi, Martin H. Voss, Fengshen Kuo et al. · Cancer Discovery · 2019 · 286 citations

Medicine, Oncology, Pharmacology +17

Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study

Alejandro Sánchez, Helena Furberg, Fengshen Kuo et al. · The Lancet Oncology · 2019 · 177 citations · Full text

Medicine, Molecular Medicine, Oncology +16

Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study

Martin H. Voss, Albert Reising, Parul Patel et al. · The Lancet Oncology · 2018 · 145 citations

Medicine, Bioinformatics, Oncology +16

Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms

James C. Yao, Jonathan Strosberg, Nicola Fazio et al. · Endocrine Related Cancer · 2021 · 106 citations

Medicine, Oncology, Pharmacology +17

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

James C. Yao, Jonathan Strosberg, Nicola Fazio et al. · Annals of Oncology · 2018 · 75 citations · Full text

Medicine, Oncology, Pharmacology +14